Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.67 |
| ▸ | KDR | P35968 | 8/20 | 0.67 |
| ▸ | AXL | P30530 | 4/20 | 0.67 |
| ▸ | KIT | P10721 | 2/20 | 0.65 |
| ▸ | FLT3 | P36888 | 2/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.65 |
| ▸ | MERTK | Q12866 | 1/20 | 0.63 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.57 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284919 | 0.86 | MET (0.87) | METKDR | |
| SCHEMBL16381018 | 0.83 | MET (0.75) | METKDRAXLKITFLT3 | |
| SCHEMBL12376877 | 0.82 | MET (0.72) | METKDRAXLKITFLT3 | |
| SCHEMBL14205647 | 0.81 | MET (0.60) | METKDRAXLKITFLT3 | |
| SCHEMBL18256939 | 0.81 | MET (0.82) | METKDRAXLKITFLT3 | |
| SCHEMBL24444555 | 0.80 | MET (0.77) | METKDRAXLKITFLT3 | |
| Exelixis SCHEMBL371899 | 0.80 | MET (1.00) | METKDRAXLKITFLT3 | |
| Exelixis SCHEMBL29693473 | 0.80 | MET (1.00) | METKDRAXLKITFLT3 | |
| SCHEMBL22766339 | 0.80 | MET (0.74) | METKDRAXLKITFLT3 | |
| SCHEMBL372035 | 0.80 | MET (0.74) | METKDRAXLKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | MET 142/4885KDR 419/4885AXL 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.